The combination of pavunalimab and XmAb23104 (PD-1/ICOS) antibody is under evaluation in a phase 1/2 trial in patients with melanoma who previously received prior ICIs (NCT05695898) (Table 3). This evidence concerns the gene PDCD1 and melanoma.